Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

Streamlined pharmacologic recommendations challenge the stepwise approach for moderately to severely active disease.

An update from SinoMab Bioscience Ltd. ( ($HK:3681) ) is now available. SinoMab BioScience Limited announced that its Investigational New Drug ...

New approaches hurdle biological barriers to attack recalcitrant targets to tackle difficult-to-treat and recurrent cancers.

Crofelemer can potentially extend lives of MVID patients – infants and children who face the lethal natural history of the disease Parenteral support reduction of up to 37% is groundbreaking; No ...

Identifying the mechanisms of action driving a drug’s anti-cancer efficacy is critical for identifying optimal biomarkers, indications, and combinations for clinical success. Yet, systematically ...

Abstract: Objectives: To explore the possible mechanism of Shenling Baizhu San (SLBZS) in the treatment of diarrheal irritable bowel syndrome (IBS-D) by network pharmacology and molecular docking ...

Please provide your email address to receive an email when new articles are posted on . In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the potential of tumor necrosis factor-like ...